What is the recommended diagnostic workup and treatment strategy for a patient with lung cancer who presents with a multifocal jejunal mass?

Lung Cancer with Multifocal Jejunal Mass: Diagnostic and Treatment Approach

A patient with lung cancer presenting with multifocal jejunal masses requires immediate surgical evaluation for potential complications (perforation, intussusception, bleeding) followed by histologic confirmation of metastatic disease, which fundamentally changes staging to stage IV and mandates systemic therapy rather than curative-intent treatment.

Immediate Clinical Assessment

The presentation of jejunal masses in a lung cancer patient demands urgent evaluation for surgical emergencies:

• Acute abdomen signs: Assess for perforation peritonitis, which occurs with jejunal metastases 1
• Intussusception: Look for colicky abdominal pain, distention, decreased bowel sounds, and "target mass" on CT 2, 3, 4
• Gastrointestinal bleeding: Check hemoglobin and stool for occult blood, as severe anemia requiring transfusion can occur 5
• Obstructive symptoms: Evaluate for ileus, vomiting, and absent defecation 4

Diagnostic Workup

Imaging Strategy

CT abdomen/pelvis with contrast is the primary imaging modality to characterize the jejunal lesions and identify complications. Look specifically for:

• "Target sign" indicating intussusception 3, 4
• Free air suggesting perforation 1
• Bowel wall thickening and mass lesions 2

PET-CT can identify unexpected metastatic sites with intense FDG uptake in jejunal lesions, though this is typically already performed during lung cancer staging 3

Tissue Diagnosis

Histologic confirmation is mandatory because jejunal metastases fundamentally alter prognosis and treatment. Options include:

• Surgical resection specimen (if emergency surgery required) 2, 1, 4
• Double-balloon endoscopy with biopsy (if patient stable) 5
• Immunohistochemistry to confirm lung origin: TTF-1+, Napsin-A+, CK7+/CK20- pattern distinguishes pulmonary from primary GI malignancy 6

Critical caveat: Adenosquamous carcinomas can show divergent differentiation across metastatic sites, requiring comprehensive sampling 6

Staging Implications

The presence of jejunal metastases upstages disease to M1c, stage IVB, regardless of the primary lung tumor characteristics 5. This eliminates curative surgical options for the lung primary and shifts management entirely to systemic therapy.

Treatment Strategy

Surgical Management

Emergency surgery is indicated for:

• Perforation with peritonitis 1
• Intussusception causing obstruction 2, 3, 4
• Uncontrolled bleeding despite transfusion 5

Perform segmental jejunal resection with primary anastomosis 2, 4. One case demonstrated long-term survival after sequential resections of jejunal then duodenal metastases, but this is exceptional 7.

Systemic Therapy

Treatment follows standard stage IV NSCLC algorithms based on histology and molecular profile 8:

For Non-Squamous NSCLC (most common with jejunal metastases):

1. Obtain molecular testing: EGFR, ALK, ROS1, BRAF, PD-L1 expression 8

2. If driver mutation positive: Use targeted therapy per guidelines

   • EGFR mutations: Osimertinib [I, A; MCBS 4] 8
   • ALK translocations: ALK inhibitors per algorithm 8

3. If driver mutation negative, PS 0-1:

   • PD-L1 ≥50%: Pembrolizumab monotherapy or combination with platinum-based chemotherapy 8
   • PD-L1 <50%: Platinum-based chemotherapy with immunotherapy combinations (pembrolizumab/pemetrexed/platinum or atezolizumab/bevacizumab/carboplatin/paclitaxel) 8
   • Standard option: Carboplatin/pemetrexed or carboplatin/nab-paclitaxel for 4-6 cycles 8

4. Upon progression (PS 0-2):

   • Nivolumab [I, A, MCBS 5] 8
   • Atezolizumab [I, A; MCBS 5] (PS 0-1) 8
   • Pembrolizumab if PD-L1 >1% [I, A; MCBS 5] 8
   • Docetaxel [I, B] 8

Real-world example: One patient with jejunal metastases received carboplatin/paclitaxel/ipilimumab/nivolumab with good response over 2 years 5

Prognostic Considerations

Jejunal metastases indicate extremely poor prognosis:

• Median survival approximately 2 months with symptomatic GI metastases 6
• Intussusception portends poor outcome regardless of management 2
• Exceptional long-term survivors exist with aggressive multimodal treatment 7, 5

Critical Pitfalls to Avoid

1. Do not assume jejunal masses are primary GI malignancy without immunohistochemistry—this fundamentally changes treatment 6
2. Do not delay surgical consultation when acute abdomen signs present—perforation and intussusception require emergency intervention 2, 1
3. Do not overlook divergent histology in adenosquamous carcinomas across different metastatic sites 6
4. Do not pursue curative-intent lung resection once jejunal metastases confirmed—this is stage IV disease requiring systemic therapy 5